Developing small-molecule probes for protein arginine methyltransferases

开发蛋白质精氨酸甲基转移酶的小分子探针

基本信息

批准号：
8959432
负责人：
Qiu Wang
金额：
$ 20.12万
依托单位：
DUKE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-07-01 至 2017-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8959432
关键词：
Antibodies Arginine Binding Biochemical Biological Assay Biological Markers Cancer Biology Cell Proliferation Cells Cellular Assay Cellular biology Chemicals Collaborations Collection DNA repair protein Development Diagnosis Diagnostic Future Genes Goals Grant Health Histones Human Individual Investigation LNCaP Lead Libraries Literature Lysine Malignant Neoplasms Malignant neoplasm of prostate Mediating Messenger RNA Methionine Methylation Methyltransferase Molecular Biology Monitor Neoplasm Metastasis Oncogene Proteins Oncogenes Oncogenic Pharmaceutical Chemistry Physiological Play Proliferating Prostate carcinoma Prostate-Specific Antigen Protein translocation Protein-Arginine N-Methyltransferase Proteins Proteomics RNA Splicing Recombinants Research Role Signal Transduction Skeleton Small Interfering RNA Structure Synthesis Chemistry Testing Therapeutic Therapeutic Agents Time Transcriptional Regulation assay development base cancer cell cancer therapy coactivator-associated arginine methyltransferase 1 cofactor computational chemistry design in vitro activity in vivo inhibitor/antagonist malignant breast neoplasm methyl group novel novel diagnostics overexpression programs small molecule therapeutic target tool transcription factor tumor progression

项目摘要

DESCRIPTION (provided by applicant): The long-term goal of our research program is to establish a platform targeting protein arginine methyltransferases (PRMTs) that develops small-molecule probes to investigate PRMTs as viable therapeutic targets and to provide lead compounds toward developing PRMT-based new diagnosis and treatment in cancers. The objective of this proposal is to validate a general structure-based approach for developing inhibitors of various PRMTs and to identify selective small-molecule inhibitors of CARM1 for investigating therapeutic potentials of chemical inhibition of CARM1 in cancer. The proposed approach builds upon our existing expertise in synthetic chemistry, assay development, and molecular and cell biology, and leverages our strong collaboration with experts in cancer biology, computation and proteomics. The central hypothesis of this proposal is that small molecules could modulate the function of specific PRMTs by interfering the selective binding of individual PRMT with co-factor SAM methyl donor or arginine substrate. To accomplish the objective of this application the following two specific aims will be pursued. Aim 1) Construct a collection of SAM-mimic and arginine mimic compounds targeting chemical inhibition of PRMTs. Aim 2) Identify CARM1 inhibitors and validate therapeutic potentials of chemical inhibition of CARM1 in cancers. Through this exploratory grant, the identification of novel small-molecule inhibitors of CARM1 will validate the general applicability of the proposed structure-based approach for developing inhibitors for various PRMTs of promising cancer-therapeutic targets. Furthermore, the identified small-molecule inhibitors of CARM1 will, for the first time, provide cell-active lead compounds for the discovery of new diagnostic biomarkers and therapeutic treatment for CARM1-assoscaited breast and prostate cancers.

描述（由申请人提供）：我们研究计划的长期目标是建立一个针对蛋白质精氨酸甲基转移酶（PRMT）的平台，开发小分子探针来研究 PRMT 作为可行的治疗靶点，并为开发 PRMT 提供先导化合物。该提案的目的是验证用于开发各种 PRMT 抑制剂的通用基于结构的方法，并确定用于研究的 CARM1 选择性小分子抑制剂。所提出的方法基于我们在合成化学、分析开发以及分子和细胞生物学方面的现有专业知识，并利用了我们与癌症生物学、计算和蛋白质组学专家的密切合作。该提议认为，小分子可以通过干扰单个 PRMT 与辅因子 SAM 甲基供体或精氨酸底物的选择性结合来调节特定 PRMT 的功能。为了实现本申请的目标，将追求以下两个具体目标。目标 1) 构建一系列针对 PRMT 化学抑制的 SAM 模拟化合物和精氨酸模拟化合物。目标 2) 鉴定 CARM1 抑制剂并验证 CARM1 化学抑制在癌症中的治疗潜力。 CARM1 抑制剂将验证所提出的基于结构的方法的普遍适用性，用于开发有希望的癌症治疗靶点的各种 PRMT 抑制剂。此外，还验证了已确定的小分子。 CARM1 抑制剂将首次为 CARM1 相关乳腺癌和前列腺癌的新诊断生物标志物的发现和治疗提供细胞活性先导化合物。